ABBOTT LABORATORIES — Director's Dealing 2019

Jun 6, 2019

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: ABBOTT LABORATORIES (ABT)
CIK: 0000001800
Period of Report: 2019-06-03

Reporting Person: Wainer Andrea F (Executive Vice President)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common shares without par value	30481	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Option (right to buy)	$47	2025-02-19	Common shares (47226)		Direct
Option (right to buy)	$38.40	2026-02-18	Common shares (75000)		Direct
Option (right to buy)	$44.40	2027-02-16	Common shares (53271)		Direct
Option (right to buy)	$59.94	2028-02-15	Common shares (64449)		Direct
Option (right to buy)	$75.90	2029-02-21	Common shares (47738)		Direct

Footnotes

F1: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 15,742 on February 20, 2016, 15,742 on February 20, 2017, and 15,742 on February 20, 2018.

F2: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 25,000 on February 19, 2017, 25,000 on February 19, 2018, and 25,000 on February 19, 2019.

F3: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 17,757 and 17,757 on February 17, 2018 and February 17, 2019, respectively, and an increment of 17,757 becomes exercisable on February 17, 2020.

F4: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in an annual increment of 21,483 on February 16, 2019, and annual increments of 21,483 and 21,483 become exercisable on February 16, 2020 and February 16, 2021, respectively.

F5: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 15,912 on February 22, 2020, 15,913 on February 22, 2021, and 15,913 on February 22, 2022.